Literature DB >> 19603419

Meta-analysis of brain-derived neurotrophic factor p.Val66Met in adult ADHD in four European populations.

C Sánchez-Mora1,2, M Ribasés1,2, J A Ramos-Quiroga1,3, M Casas1,3, R Bosch1, A Boreatti-Hümmer4, M Heine4, C P Jacob4, K-P Lesch4, O B Fasmer5,6, P M Knappskog7,8, J J Sandra Kooij9, C Kan10, J K Buitelaar10, E Mick11, P Asherson12, S V Faraone13, B Franke14,15, S Johansson7,16, J Haavik5,16, A Reif4, M Bayés17,18,19, B Cormand20,21,22.   

Abstract

Attention-deficit hyperactivity disorder (ADHD) is a multifactorial, neurodevelopmental disorder that often persists into adolescence and adulthood and is characterized by inattention, hyperactivity and impulsiveness. Before the advent of the first genome-wide association studies in ADHD, genetic research had mainly focused on candidate genes related to the dopaminergic and serotoninergic systems, although several other genes had also been assessed. Pharmacological data, analysis of animal models and association studies suggest that Brain-Derived Neurotrophic Factor (BDNF) is also a strong candidate gene for ADHD. Several polymorphisms in BDNF have been reported and studied in psychiatric disorders but the most frequent is the p.Val66Met (rs6265G > A) single nucleotide polymorphism (SNP), with functional effects on the intracellular trafficking and secretion of the protein. To deal with the inconsistency raised among different case-control and family-based association studies regarding the p.Val66Met contribution to ADHD, we performed a meta-analysis of published as well as unpublished data from four different centers that are part of the International Multicentre Persistent ADHD CollaboraTion (IMpACT). A total of 1,445 adulthood ADHD patients and 2,247 sex-matched controls were available for the study. No association between the p.Val66Met polymorphism and ADHD was found in any of the four populations or in the pooled sample. The meta-analysis also showed that the overall gene effect for ADHD was not statistically significant when gender or comorbidity with mood disorders were considered. Despite the potential role of BDNF in ADHD, our data do not support the involvement of p.Val66Met in the pathogenesis of this neuropsychiatric disorder. (c) 2009 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19603419     DOI: 10.1002/ajmg.b.31008

Source DB:  PubMed          Journal:  Am J Med Genet B Neuropsychiatr Genet        ISSN: 1552-4841            Impact factor:   3.568


  16 in total

1.  Genetics of serum BDNF: meta-analysis of the Val66Met and genome-wide association study.

Authors:  Antonio Terracciano; Maria Grazia Piras; Monia Lobina; Antonella Mulas; Osorio Meirelles; Angelina R Sutin; Wayne Chan; Serena Sanna; Manuela Uda; Laura Crisponi; David Schlessinger
Journal:  World J Biol Psychiatry       Date:  2011-11-02       Impact factor: 4.132

2.  Changes in the serum levels of brain-derived neurotrophic factor in adults with attention deficit hyperactivity disorder after treatment with atomoxetine.

Authors:  Josep Antoni Ramos-Quiroga; Margarida Corominas-Roso; Gloria Palomar; Nuria Gomez-Barros; Marta Ribases; Cristina Sanchez-Mora; Rosa Bosch; Mariana Nogueira; Montserrat Corrales; Sergi Valero; Miguel Casas
Journal:  Psychopharmacology (Berl)       Date:  2013-11-08       Impact factor: 4.530

3.  Epigenetics in Developmental Disorder: ADHD and Endophenotypes.

Authors:  Trevor Archer; Marlene Oscar-Berman; Kenneth Blum
Journal:  J Genet Syndr Gene Ther       Date:  2011-06-30

4.  BDNF concentrations and daily fluctuations differ among ADHD children and respond differently to methylphenidate with no relationship with depressive symptomatology.

Authors:  Isabel Cubero-Millán; María-José Ruiz-Ramos; Antonio Molina-Carballo; Sylvia Martínez-Serrano; Luisa Fernández-López; Irene Machado-Casas; Pilar Tortosa-Pinto; Aida Ruiz-López; Juan-de-Dios Luna-Del-Castillo; José Uberos; Antonio Muñoz-Hoyos
Journal:  Psychopharmacology (Berl)       Date:  2016-11-03       Impact factor: 4.530

5.  Differential Behavioral and Biochemical Responses to Caffeine in Male and Female Rats from a Validated Model of Attention Deficit and Hyperactivity Disorder.

Authors:  Fernanda Nunes; Daniela Pochmann; Amanda Staldoni Almeida; Daniela Melo Marques; Lisiane de Oliveira Porciúncula
Journal:  Mol Neurobiol       Date:  2018-03-20       Impact factor: 5.590

6.  Serum brain-derived neurotrophic factor, glial-derived neurotrophic factor, nerve growth factor, and neurotrophin-3 levels in children with attention-deficit/hyperactivity disorder.

Authors:  Ayhan Bilgiç; Aysun Toker; Ümit Işık; İbrahim Kılınç
Journal:  Eur Child Adolesc Psychiatry       Date:  2016-08-25       Impact factor: 4.785

Review 7.  European consensus statement on diagnosis and treatment of adult ADHD: The European Network Adult ADHD.

Authors:  Sandra J J Kooij; Susanne Bejerot; Andrew Blackwell; Herve Caci; Miquel Casas-Brugué; Pieter J Carpentier; Dan Edvinsson; John Fayyad; Karin Foeken; Michael Fitzgerald; Veronique Gaillac; Ylva Ginsberg; Chantal Henry; Johanna Krause; Michael B Lensing; Iris Manor; Helmut Niederhofer; Carlos Nunes-Filipe; Martin D Ohlmeier; Pierre Oswald; Stefano Pallanti; Artemios Pehlivanidis; Josep A Ramos-Quiroga; Maria Rastam; Doris Ryffel-Rawak; Steven Stes; Philip Asherson
Journal:  BMC Psychiatry       Date:  2010-09-03       Impact factor: 3.630

8.  Case-control genome-wide association study of persistent attention-deficit hyperactivity disorder identifies FBXO33 as a novel susceptibility gene for the disorder.

Authors:  Cristina Sánchez-Mora; Josep A Ramos-Quiroga; Rosa Bosch; Montse Corrales; Iris Garcia-Martínez; Mariana Nogueira; Mireia Pagerols; Gloria Palomar; Vanesa Richarte; Raquel Vidal; Alejandro Arias-Vasquez; Mariona Bustamante; Joan Forns; Silke Gross-Lesch; Monica Guxens; Anke Hinney; Martine Hoogman; Christian Jacob; Kaya K Jacobsen; Cornelis C Kan; Lambertus Kiemeney; Sarah Kittel-Schneider; Marieke Klein; Marten Onnink; Olga Rivero; Tetyana Zayats; Jan Buitelaar; Stephen V Faraone; Barbara Franke; Jan Haavik; Stefan Johansson; Klaus-Peter Lesch; Andreas Reif; Jordi Sunyer; Mònica Bayés; Miguel Casas; Bru Cormand; Marta Ribasés
Journal:  Neuropsychopharmacology       Date:  2014-10-06       Impact factor: 7.853

Review 9.  The genetics of attention deficit/hyperactivity disorder in adults, a review.

Authors:  B Franke; S V Faraone; P Asherson; J Buitelaar; C H D Bau; J A Ramos-Quiroga; E Mick; E H Grevet; S Johansson; J Haavik; K-P Lesch; B Cormand; A Reif
Journal:  Mol Psychiatry       Date:  2011-11-22       Impact factor: 15.992

Review 10.  Protection from genetic diathesis in attention-deficit/hyperactivity disorder: possible complementary roles of exercise.

Authors:  Anna-Sophie Rommel; Jeffrey M Halperin; Jonathan Mill; Philip Asherson; Jonna Kuntsi
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2013-07-31       Impact factor: 8.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.